ID: ALA1673027
Chembl Id: CHEMBL1673027
PubChem CID: 10424810
Max Phase: Preclinical
Molecular Formula: C17H11F2NO2
Molecular Weight: 299.28
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(c1ccccc1)c1ccn(-c2cc(F)c(O)c(F)c2)c1
Standard InChI: InChI=1S/C17H11F2NO2/c18-14-8-13(9-15(19)17(14)22)20-7-6-12(10-20)16(21)11-4-2-1-3-5-11/h1-10,22H
Standard InChI Key: DGPWCCFKELIMEO-UHFFFAOYSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 299.28 | Molecular Weight (Monoisotopic): 299.0758 | AlogP: 3.69 | #Rotatable Bonds: 3 |
| Polar Surface Area: 42.23 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 8.26 | CX Basic pKa: | CX LogP: 4.38 | CX LogD: 4.32 |
| Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.75 | Np Likeness Score: -0.71 |
| 1. Nicolaou I, Zika C, Demopoulos VJ.. (2004) [1-(3,5-difluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone as a bioisostere of a carboxylic acid aldose reductase inhibitor., 47 (10): [PMID:15115413] [10.1021/jm031060t] |
| 2. Chatzopoulou M, Mamadou E, Juskova M, Koukoulitsa C, Nicolaou I, Stefek M, Demopoulos VJ.. (2011) Structure-activity relations on [1-(3,5-difluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone. The effect of methoxy substitution on aldose reductase inhibitory activity and selectivity., 19 (4): [PMID:21288726] [10.1016/j.bmc.2011.01.009] |
| 3. Meanwell NA.. (2011) Synopsis of some recent tactical application of bioisosteres in drug design., 54 (8): [PMID:21413808] [10.1021/jm1013693] |
| 4. Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A.. (2020) Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus., 207 [PMID:32871344] [10.1016/j.ejmech.2020.112742] |
Source(1):
